Vir Biotechnology, Inc. VIR Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $283.04M+17.4% | $241.07M+34.5% | $179.26M-41.5% | $306.28M-16.8% | $368M+15.5% | ||
| $196.28M-14.2% | $228.75M-30.2% | $327.75M-15.5% | $387.65M-25.1% | $517.37M-23.7% | ||
| $522.99M+1.7% | $514.08M-5.8% | $545.68M-25.8% | $735.71M-21.1% | $932.21M-10.6% | ||
| $53.16M-4.4% | $55.62M-4.4% | $58.2M-4.3% | $60.8M-1.4% | $61.68M-2.4% | ||
| $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | ||
| $7.78M-0.9% | $7.85M-0.9% | $7.92M-0.9% | $8M-0.9% | $8.07M-0.6% | ||
| $1.03B+2.3% | $1B-1.6% | $1.02B-14.5% | $1.19B-8.8% | $1.31B-6.5% | ||
| $5.45M-44.5% | $9.8M+43.2% | $6.85M-44.0% | $12.23M+228% | $3.73M-26.7% | ||
| $73.56M-20.7% | $92.82M+23.4% | $75.22M-28.4% | $105M-23.5% | $137.29M+14.7% | ||
| $212.82M-10.4% | $237.55M+6.4% | $223.36M-8.9% | $245.06M-7.1% | $263.91M+6.2% | ||
| 300M0.0% | 300M0.0% | 300M0.0% | 300M0.0% | 300M+2,142,757% | ||
| -$1.32B-10.5% | -$1.2B-3.7% | -$1.15B-16.5% | -$991.71M-12.6% | -$880.75M-15.9% | ||
| $812.77M+6.2% | $765.28M-3.9% | $796.1M-16.0% | $947.47M-9.2% | $1.04B-9.3% | ||
| $1.03B+2.3% | $1B-1.6% | $1.02B-14.5% | $1.19B-8.8% | $1.31B-6.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Vir Biotechnology, Inc. cover its short-term obligations?
- Its current ratio is 7.11 — current assets exceed current liabilities.
- Where does Vir Biotechnology, Inc.'s balance sheet data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.